SOAT1 and COVID-19: To confirm this hypothesis, as well as to ascertain the contribution of each cytokine to the observed effects, specific neutralizing antibodies were added to CM_S1; in addition, the JAK/STAT inhibitor baricitinib, a drug approved for COVID-19 treatment, was also tested (Figure 5).